216 related articles for article (PubMed ID: 30424709)
1. "TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure".
Horton JS; Shiraishi T; Alfulaij N; Small-Howard AL; Turner HC; Kurokawa T; Mori Y; Stokes AJ
Channels (Austin); 2019 Dec; 13(1):1-16. PubMed ID: 30424709
[TBL] [Abstract][Full Text] [Related]
2. Mice lacking functional TRPV1 are protected from pressure overload cardiac hypertrophy.
Buckley CL; Stokes AJ
Channels (Austin); 2011; 5(4):367-74. PubMed ID: 21814047
[TBL] [Abstract][Full Text] [Related]
3. Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice.
Horton JS; Buckley CL; Stokes AJ
Channels (Austin); 2013 Jan; 7(1):17-22. PubMed ID: 23221478
[TBL] [Abstract][Full Text] [Related]
4. Mitogen-Activated Protein Kinase and Intracellular Polyamine Signaling Is Involved in TRPV1 Activation-Induced Cardiac Hypertrophy.
Chen M; Xin J; Liu B; Luo L; Li J; Yin W; Li M
J Am Heart Assoc; 2016 Jul; 5(8):. PubMed ID: 27473037
[TBL] [Abstract][Full Text] [Related]
5. Genetic ablation of TRPV1 exacerbates pressure overload-induced cardiac hypertrophy.
Zhong B; Rubinstein J; Ma S; Wang DH
Biomed Pharmacother; 2018 Mar; 99():261-270. PubMed ID: 29334670
[TBL] [Abstract][Full Text] [Related]
6. Cold stress accentuates pressure overload-induced cardiac hypertrophy and contractile dysfunction: role of TRPV1/AMPK-mediated autophagy.
Lu S; Xu D
Biochem Biophys Res Commun; 2013 Dec; 442(1-2):8-15. PubMed ID: 24211590
[TBL] [Abstract][Full Text] [Related]
7. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.
Takimoto E; Champion HC; Li M; Belardi D; Ren S; Rodriguez ER; Bedja D; Gabrielson KL; Wang Y; Kass DA
Nat Med; 2005 Feb; 11(2):214-22. PubMed ID: 15665834
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart.
Kinoshita H; Kuwahara K; Nishida M; Jian Z; Rong X; Kiyonaka S; Kuwabara Y; Kurose H; Inoue R; Mori Y; Li Y; Nakagawa Y; Usami S; Fujiwara M; Yamada Y; Minami T; Ueshima K; Nakao K
Circ Res; 2010 Jun; 106(12):1849-60. PubMed ID: 20448219
[TBL] [Abstract][Full Text] [Related]
9. Cardiac-specific overexpression of caveolin-3 attenuates cardiac hypertrophy and increases natriuretic peptide expression and signaling.
Horikawa YT; Panneerselvam M; Kawaraguchi Y; Tsutsumi YM; Ali SS; Balijepalli RC; Murray F; Head BP; Niesman IR; Rieg T; Vallon V; Insel PA; Patel HH; Roth DM
J Am Coll Cardiol; 2011 May; 57(22):2273-83. PubMed ID: 21616289
[TBL] [Abstract][Full Text] [Related]
10. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response.
Beider K; Rosenberg E; Dimenshtein-Voevoda V; Sirovsky Y; Vladimirsky J; Magen H; Ostrovsky O; Shimoni A; Bromberg Z; Weiss L; Peled A; Nagler A
J Hematol Oncol; 2020 Nov; 13(1):158. PubMed ID: 33239060
[TBL] [Abstract][Full Text] [Related]
11. Deficiency of Cardiac Natriuretic Peptide Signaling Promotes Peripartum Cardiomyopathy-Like Remodeling in the Mouse Heart.
Otani K; Tokudome T; Kamiya CA; Mao Y; Nishimura H; Hasegawa T; Arai Y; Kaneko M; Shioi G; Ishida J; Fukamizu A; Osaki T; Nagai-Okatani C; Minamino N; Ensho T; Hino J; Murata S; Takegami M; Nishimura K; Kishimoto I; Miyazato M; Harada-Shiba M; Yoshimatsu J; Nakao K; Ikeda T; Kangawa K
Circulation; 2020 Feb; 141(7):571-588. PubMed ID: 31665900
[TBL] [Abstract][Full Text] [Related]
12. TRPV1-antagonist AMG9810 promotes mouse skin tumorigenesis through EGFR/Akt signaling.
Li S; Bode AM; Zhu F; Liu K; Zhang J; Kim MO; Reddy K; Zykova T; Ma WY; Carper AL; Langfald AK; Dong Z
Carcinogenesis; 2011 May; 32(5):779-85. PubMed ID: 21349818
[TBL] [Abstract][Full Text] [Related]
13. The Complement System Component C5a Produces Thermal Hyperalgesia via Macrophage-to-Nociceptor Signaling That Requires NGF and TRPV1.
Shutov LP; Warwick CA; Shi X; Gnanasekaran A; Shepherd AJ; Mohapatra DP; Woodruff TM; Clark JD; Usachev YM
J Neurosci; 2016 May; 36(18):5055-70. PubMed ID: 27147658
[TBL] [Abstract][Full Text] [Related]
14. Increased transient receptor potential vanilloid type 1 (TRPV1) channel expression in hypertrophic heart.
Thilo F; Liu Y; Schulz N; Gergs U; Neumann J; Loddenkemper C; Gollasch M; Tepel M
Biochem Biophys Res Commun; 2010 Oct; 401(1):98-103. PubMed ID: 20833132
[TBL] [Abstract][Full Text] [Related]
15. Transient Receptor Potential Vanilloid Type 1 Protects Against Pressure Overload-Induced Cardiac Hypertrophy by Promoting Mitochondria-Associated Endoplasmic Reticulum Membranes.
Wang Y; Li X; Xu X; Qu X; Yang Y
J Cardiovasc Pharmacol; 2022 Sep; 80(3):430-441. PubMed ID: 35881904
[TBL] [Abstract][Full Text] [Related]
16. Prevention of PKG-1α Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation.
Nakamura T; Zhu G; Ranek MJ; Kokkonen-Simon K; Zhang M; Kim GE; Tsujita K; Kass DA
Circ Heart Fail; 2018 Mar; 11(3):e004740. PubMed ID: 29545395
[TBL] [Abstract][Full Text] [Related]
17. The sympathetic nervous system is controlled by transient receptor potential vanilloid 1 in the regulation of body temperature.
Alawi KM; Aubdool AA; Liang L; Wilde E; Vepa A; Psefteli MP; Brain SD; Keeble JE
FASEB J; 2015 Oct; 29(10):4285-98. PubMed ID: 26136480
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic antagonism of the oral aversive taste-directed response to capsaicin in a mouse brief access taste aversion assay.
Long DJ; Devantier HR; Brennan FX; Bryant RW; Salemme FR; Palmer RK
J Pharmacol Exp Ther; 2010 Feb; 332(2):525-30. PubMed ID: 19903834
[TBL] [Abstract][Full Text] [Related]
19. Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling.
Franco V; Chen YF; Oparil S; Feng JA; Wang D; Hage F; Perry G
Hypertension; 2004 Nov; 44(5):746-50. PubMed ID: 15452027
[TBL] [Abstract][Full Text] [Related]
20. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
Nakagawa H; Oberwinkler H; Nikolaev VO; Gaßner B; Umbenhauer S; Wagner H; Saito Y; Baba HA; Frantz S; Kuhn M
Circ Heart Fail; 2014 Sep; 7(5):814-21. PubMed ID: 25027872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
